A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Condition(s):Choroidal NeovascularizationLast Updated:November 12, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Choroidal NeovascularizationLast Updated:November 12, 2020Completed
Condition(s):Choroidal NeovascularizationLast Updated:June 15, 2012Completed
Condition(s):Choroidal Neovascularization (CNV)Last Updated:August 26, 2016Completed
Condition(s):Pathological Myopic Choroidal NeovascularizationLast Updated:June 10, 2021Unknown status
Condition(s):Subfoveal Choroidal NeovascularizationLast Updated:June 30, 2009Unknown status
Condition(s):Myopic Choroidal NeovascularizationLast Updated:November 25, 2008Completed
Condition(s):Choroidal NeovascularizationLast Updated:February 3, 2006Unknown status
Condition(s):Choroidal NeovascularizationLast Updated:December 31, 2015Withdrawn
Condition(s):Choroidal Neovascularization Secondary to Pathologic MyopiaLast Updated:March 19, 2024Recruiting
Condition(s):Choroidal Neovascularization; Mineralocorticoid ExcessLast Updated:June 19, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.